On Feb. 15, 2022, Pfizer announced that the European Medicines Agency had approved the companyﾒs 20-valent pneumococcal conjugate vaccine (PCV20), marketed in the European Union under the brand name APEXXNAR. The vaccine was approved for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcuspneumoniae in individuals 18 years of age and older.